A new ketogenic formulation improves functional outcome and reduces tissue loss following traumatic brain injury in adult mice

Traumatic brain injury (TBI) leads to neurological impairment, with no satisfactory treatments available. Classical ketogenic diets (KD), which reduce reliance on carbohydrates and provide ketones as fuel, have neuroprotective potential, but their high fat content reduces compliance, and experimenta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Theranostics 2021-01, Vol.11 (1), p.346-360
Hauptverfasser: Thau-Zuchman, Orli, Svendsen, Linda, Dyall, Simon C, Paredes-Esquivel, Ursula, Rhodes, Molly, Priestley, John V, Feichtinger, René G, Kofler, Barbara, Lotstra, Susanne, Verkuyl, J Martin, Hageman, Robert J, Broersen, Laus M, van Wijk, Nick, Silva, Jose P, Tremoleda, Jordi L, Michael-Titus, Adina T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Traumatic brain injury (TBI) leads to neurological impairment, with no satisfactory treatments available. Classical ketogenic diets (KD), which reduce reliance on carbohydrates and provide ketones as fuel, have neuroprotective potential, but their high fat content reduces compliance, and experimental evidence suggests they protect juvenile brain against TBI, but not adult brain, which would strongly limit their applicability in TBI. We designed a new-KD with a fat to carbohydrate plus protein ratio of 2:1, containing medium chain triglycerides (MCT), docosahexaenoic acid (DHA), low glycaemic index carbohydrates, fibres and the ketogenic amino acid leucine, and evaluated its neuroprotective potential in adult TBI. Adult male C57BL6 mice were injured by controlled cortical impact (CCI) and assessed for 70 days, during which they received a control diet or the new-KD. The new-KD, that markedly increased plasma Beta-hydroxybutyrate (β-HB), significantly attenuated sensorimotor deficits and corrected spatial memory deficit. The lesion size, perilesional inflammation and oxidation were markedly reduced. Oligodendrocyte loss appeared to be significantly reduced. TBI activated the mTOR pathway and the new-KD enhanced this increase and increased histone acetylation and methylation. The behavioural improvement and tissue protection provide proof of principle that this new formulation has therapeutic potential in adult TBI.
ISSN:1838-7640
1838-7640
DOI:10.7150/thno.48995